CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 363 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00741104
NCT00741104N/ACompleted
CompareCT.gov

A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients

Merck Sharp & Dohme LLC·observational·Posted Aug 26, 2008·Updated Jan 4, 2017

In Brief

An observational study evaluating Infliximab for Rheumatoid Arthritis. Completed, enrolled 363 participants.

Detailed Summary

This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study. Patients will be asked a variety of questions regarding their treatment dosing and disease activity, and then asked whether or not they would consider participating in a dose reduction study. Patients in this study will be described in terms of demographic and disease characteristics.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 26, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.8 years ago

Interventions

Infliximabdrug

Treatment of RA with Infliximab according to and under normal routine clinical practice.